Results 41 to 50 of about 62,042 (258)

Short‐Term Response to Biologic Therapy in Psoriatic Arthritis Is Not Influenced by Disease Duration at Initiation of Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective We aimed to determine whether the short‐term response to biologics in biologic‐naive psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods Patients with PsA who started on biologic therapy from the year 2000 to 2025 were included for analysis.
Sung Min Cho   +4 more
wiley   +1 more source

HMG-Coenzyme A Reductase as a Drug Target for the Prevention of Ankylosing Spondylitis

open access: yesFrontiers in Cell and Developmental Biology, 2021
Statins are an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). Growing evidence indicates that statins may have an anti-inflammatory effect.
Zhenyu Zhong   +8 more
doaj   +1 more source

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

Evaluation of usability, feasibility and acceptance of the digital training diary Trainingslog for individuals with axSpA: a mixed-method study

open access: yesBMC Rheumatology
Background Physical activity (PA), including regular exercise, is essential for the successful management of axial spondyloarthritis (axSpA). To promote a physically active lifestyle, a digital training diary (Trainingslog) was developed in an user ...
Neva Pfyl   +3 more
doaj   +1 more source

Pseudoarthrosis in ankylosing spondylitis. [PDF]

open access: yesAnnals of the Rheumatic Diseases, 1994
published_or_final_version
Luk, KDK, Peh, WCG
openaire   +3 more sources

Examining the Interchangeability of Two Different Patient‐Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective The goal of this study was to determine if patient global assessment (PGA) scores reported by patients with axial spondyloarthritis (AxSpA) before the development of the AxSpA Disease Activity Score (ASDAS) can be used as a substitute for the global item of the ASDAS formula.
Connor Vershel   +8 more
wiley   +1 more source

Moyamoya disease associated with ankylosing spondylitis in a 9-year-old child: a case report

open access: yesChinese Neurosurgical Journal, 2017
Background Ankylosing spondylitis was reported to associate with an increased risk of cerebrovascular diseases. In this article, we aimed to report the first case of ankylosing spondylitis associated with moyamoya disease treated with encephalo ...
Fan Yang, Peicong Ge, Xun Ye
doaj   +1 more source

Epidemiology of ankylosing spondylitis: IGAS 2009

open access: yes, 2010
The International Genetics of Ankylosing Spondylitis (IGAS) meeting was held in Houston, Texas, July 25, 2009. Sixteen investigators from Asia, Australia, Europe, and North and South America presented the status of their respective cohorts of patients ...
JOHN D. REVEILLE   +5 more
core   +1 more source

Survival Outcomes in Older Adults With Axial Spondyloarthritis and Concomitant Cancer

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to determine survival outcomes in older adults with axial spondyloarthritis (axSpA) and concomitant cancer. Methods We conducted a population‐based study using Medicare claims data linked to Surveillance, Epidemiology, and End Results data to determine overall survival (OS) and cancer‐specific survival (CSS) in
Savannah Bowman   +7 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy